Literature DB >> 688274

Pharmacokinetics of BCNU in man: a preliminary study of 20 patients.

V A Levin, W Hoffman, R J Weinkam.   

Abstract

Using the technique of direct sample insertion selected ion monitoring chemical ionization mass spectroscopy, BCNU levels were measured in vivo in patients and in vitro in serum, sera ultrafiltrates, and buffered Ringer's solution. The disappearance of BCNU in vitro was found to be first-order with a half-time of 11.6 minutes (+/- 0.5 SD) in volunteers and 15.6 minutes (+/- 2.3 SD) in patients. The disappearance from serum was catalyzed by a macromolecular component of the serum and was slowed by serum lipids. Analysis of the pharmacokinetics of BCNU in 20 patients using a two-compartment open model demonstrated a volume of distribution of 3.25 liters/kg (+/- 1.69 SD), a clearance of 56 ml/minute/kg (+/- 56 SD), and a transfer constant from the central compartment to the outside (K10) OF 0.0324 MINUTE-1 (+/- 41% SD), which was close to the decomposition rate observed for BCNU in serum in vitro. The pharmacokinetics of BCNU in patients may be affected by the percent of body fat and the lipid content of the serum.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 688274

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  21 in total

Review 1.  Do anticancer agents reach the tumor target in the human brain?

Authors:  M G Donelli; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines.

Authors:  H Roed; L L Vindeløv; M Spang-Thomsen; I J Christensen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Mathematical and experimental approaches to identify and predict the effects of chemotherapy on neuroglial precursors.

Authors:  Ollivier Hyrien; Jörg Dietrich; Mark Noble
Journal:  Cancer Res       Date:  2010-11-05       Impact factor: 12.701

4.  Selective activation of human heat shock gene transcription by nitrosourea antitumor drugs mediated by isocyanate-induced damage and activation of heat shock transcription factor.

Authors:  R A Kroes; K Abravaya; J Seidenfeld; R I Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

5.  Pharmacologic studies of anticancer drugs with the human tumor stem cell assay.

Authors:  D S Alberts; S E Salmon; H S Chen; T E Moon; L Young; E A Surwit
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Distribution of Bratton-Marshall-positive material in mice following intravenous injections of nitrosoureas.

Authors:  P Kari; W R McConnell; J M Finkel; D L Hill
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Pharmacokinetics of 11C-BCNU in experimental brain tumor.

Authors:  K Sako; M Diksic; S Farrokhzad; Y L Yamamoto; W Feindel
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

8.  Morphologic, cytochemical and neurochemical characterization of the human medulloblastoma cell line TE671.

Authors:  P M Zeltzer; S L Schneider; D D Von Hoff
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

9.  Membrane and cytoplasmic changes in 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU)-sensitive and resistant human malignant glioma-derived cell lines.

Authors:  B H Smith; M Vaughan; M A Greenwood; P L Kornblith; A Robinson; N Shitara; P E McKeever
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

10.  Capillary gas chromatography and thermionic N-P-specific detection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in stability and pharmacokinetic studies.

Authors:  A El-Yazigi; C R Martin
Journal:  Pharm Res       Date:  1988-04       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.